17-31156056-A-G
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 1P and 6B. PP2BP4BP6BS2
The NM_001042492.3(NF1):āc.134A>Gā(p.Asn45Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000304 in 1,613,596 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.134A>G | p.Asn45Ser | missense_variant | Exon 2 of 58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_000267.3 | c.134A>G | p.Asn45Ser | missense_variant | Exon 2 of 57 | NP_000258.1 | ||
NF1 | NM_001128147.3 | c.134A>G | p.Asn45Ser | missense_variant | Exon 2 of 15 | NP_001121619.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152098Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251188Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135766
GnomAD4 exome AF: 0.0000308 AC: 45AN: 1461498Hom.: 0 Cov.: 33 AF XY: 0.0000358 AC XY: 26AN XY: 727074
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152098Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74308
ClinVar
Submissions by phenotype
not provided Uncertain:3
In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Observed in individuals with suspected neurofibromatosis type 1 (Sabbagh 2013); This variant is associated with the following publications: (PMID: 23913538, 30287823, 33471991) -
The NF1 c.134A>G; p.Asn45Ser variant (rs753189381) is reported in the literature in an individual affected with neurofibromatosis type I (Sabbagh 2013). This variant is found on seven chromosomes (7/282552 alleles) in the Genome Aggregation Database. The asparagine at codon 45 is moderately conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. However, due to limited information, the clinical significance of the p.Asn45Ser variant is uncertain at this time. References: Sabbagh A et al. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat. 2013;34(11):1510-1518. -
- -
Hereditary cancer-predisposing syndrome Uncertain:3
Thep.N45Svariant (also known as c.134A>G), located in coding exon 2 of theNF1gene, results from an A to G substitution at nucleotide position 134. The asparagine at codon 45 is replaced by serine, an amino acid with highly similar properties. This variant was previously identified in a French individual with Neurofibromatosis type 1 (SabbaghA, et al.Hum.Mutat.2013 Nov; 34(11):1510-8).This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position.To date, this alteration has been detected with an allele frequency of approximately 0.01% (greater than 110000 alleles tested) in our clinical cohort.This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis.Since supporting evidence is limited at this time, the clinical significance of p.N45Sremains unclear. -
- -
- -
Neurofibromatosis, type 1 Uncertain:1Benign:1
- -
- -
not specified Uncertain:1
Variant summary: NF1 c.134A>G (p.Asn45Ser) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 251188 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance.c.134A>G has been reported in the literature in an individual affected with Neurofibromatosis Type 1 (Sabbagh_2013), however segregation analysis was not performed in this family. The variant was also reported in individuals affected with breast cancer (Dorling_2021), however it was found also in several controls (Momozawa_2018, Dorling_2021). These reports do not provide unequivocal conclusions about association of the variant with Neurofibromatosis Type 1. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 10678181, 23460398, 29872168, 23913538, 30287823, 27069254, 33471991). ClinVar contains an entry for this variant (Variation ID: 229787). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at